Join the club for FREE to access the whole archive and other member benefits.

Sekar Kathiresan

Physician scientist, human geneticist and professor at Harvard Medical School.

Sekar Kathiresan, a physician scientist and a human geneticist, is the Director of the Center for Genomic Medicine (CGM) at Massachusetts General Hospital (MGH), Ofer and Shelly Nemirovsky MGH Research Scholar, Director of the Cardiovascular Disease Initiative at the Broad institute, and a Professor of Medicine at Harvard Medical School.

Dr. Kathiresan leverages human genetics to understand the root causes of heart attack and to improve preventive cardiac care.  Among his scientific contributions, Dr. Kathiresan has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention.

Visit website: http://www.kathiresanlab.org/about-sek/

 sekar-kathiresan-3501846

 skathire

See also: Academia Harvard Medical School - Graduate medical school of Harvard University

Details last updated 25-Dec-2019

Sekar Kathiresan News

Single-dose gene-editing therapy offers permanent solution to high cholesterol levels

Single-dose gene-editing therapy offers permanent solution to high cholesterol levels

New Scientist - 14-Nov-2023

Early results show promise in eliminating the need for lifelong statins

Verve Therapeutics' gene editing therapy may cure heart attacks once and for all

Verve Therapeutics' gene editing therapy may cure heart attacks once and for all

Bloomberg - 06-May-2022

Trials underway to test the safety, but affordability and acceptance of gene therapy are major concerns

Gene editing lowered blood level cholesterol and triglycerides in monkeys

Gene editing lowered blood level cholesterol and triglycerides in monkeys

New York Times - 27-Jun-2020

Could prevent not only the complications but the heart disease per se in the future

Crispr injection could reduce chance of heart attack

Crispr injection could reduce chance of heart attack

Guardian - 10-May-2019

Verve Therapeutics treatment targets PCSK9 gene